TORII PHARMACEUTICAL CO., LTD. Toevoegen aan een lijst
|
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 3.960 JPY | -0,38% |
|
+2,72% | +11,39% |
| 13/02 | LIM Advisors trekt aandeelhoudersvoorstel gedeeltelijk in | CI |
| 09/02 | Torii Pharmaceuticals verzet zich tegen aandeelhoudersvoorstel | CI |
Totale waarde
| Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Marktkapitalisatie 1 | 85.830 | 90.395 | 80.794 | 81.805 | 99.800 | 111.169 | - | - |
| Bedrijfswaarde 1 | 47.286 | 48.444 | 39.070 | 34.637 | 56.041 | 111.169 | 111.169 | 111.169 |
| K/w-verhouding | 3,14 x | 25,9 x | 24 x | 20,8 x | 24,2 x | 22,8 x | 19,7 x | 16,5 x |
| Dividendrendement | 1,57% | 1,49% | 1,67% | 3,43% | 3,38% | 3,03% | 3,03% | 3,09% |
| Marktkapitalisatie/omzet | 2 x | 2,17 x | 1,72 x | 1,67 x | 1,83 x | 1,92 x | 1,82 x | 1,66 x |
| Bedrijfswaarde/omzet | 2 x | 2,17 x | 1,72 x | 1,67 x | 1,83 x | 1,92 x | 1,82 x | 1,66 x |
| Bedrijfswaarde/EBITDA | 35,5 x | 17 x | 15,9 x | 13,6 x | 18,2 x | 17,9 x | 14,6 x | 12,1 x |
| Bedrijfswaarde/FCF | 2,12 x | 21,6 x | -48,8 x | 42,8 x | -14,5 x | 18,8 x | 20,3 x | 29,5 x |
| FCF Yield | 47,1% | 4,63% | -2,05% | 2,34% | -6,92% | 5,32% | 4,93% | 3,39% |
| Price to Book | 0,76 x | 0,79 x | 0,69 x | 0,69 x | 0,83 x | 0,92 x | 0,9 x | 0,88 x |
| Aantal aandelen (in duizenden) | 28.049 | 28.073 | 28.073 | 28.073 | 28.073 | 28.073 | - | - |
| Referentieprijs 2 | 3.060 | 3.220 | 2.878 | 2.914 | 3.555 | 3.960 | 3.960 | 3.960 |
| Datum van publicatie | 6/02/20 | 4/02/21 | 10/02/22 | 10/02/23 | 9/02/24 | - | - | - |
1JPY in Miljoen2JPY
Geschatte gegevens
Evolutie van de resultatenrekening (Jaargegevens)
| Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Omzet 1 | 42.998 | 41.700 | 46.987 | 48.896 | 54.638 | 57.800 | 61.220 | 66.900 |
| EBITDA 1 | 2.415 | 5.320 | 5.069 | 5.994 | 5.494 | 6.218 | 7.606 | 9.169 |
| Bedrijfsresultaat (EBIT) 1 | 1.430 | 4.738 | 4.656 | 5.540 | 5.035 | 6.050 | 7.095 | 8.550 |
| Operationele Marge | 3,33% | 11,36% | 9,91% | 11,33% | 9,22% | 10,47% | 11,59% | 12,78% |
| Resultaat voor belastingen (EBT) 1 | 37.700 | 4.225 | 4.767 | 5.722 | 5.593 | 6.550 | 7.592 | 9.060 |
| Nettowinst (verlies) 1 | 27.367 | 3.495 | 3.374 | 3.944 | 4.119 | 4.885 | 5.652 | 6.730 |
| Nettomarge | 63,65% | 8,38% | 7,18% | 8,07% | 7,54% | 8,45% | 9,23% | 10,06% |
| WPA 2 | 975,0 | 124,5 | 120,1 | 140,4 | 146,6 | 173,8 | 201,2 | 239,4 |
| Free Cash Flow 1 | 40.400 | 4.182 | -1.654 | 1.912 | -6.902 | 5.913 | 5.485 | 3.770 |
| FCF-marge | 93,96% | 10,03% | -3,52% | 3,91% | -12,63% | 10,23% | 8,96% | 5,64% |
| Kasstroomconversie (ebitda) | 1.672,88% | 78,61% | - | 31,9% | - | 95,09% | 72,11% | 41,12% |
| Kasstroomconversie (nettowinst) | 147,62% | 119,66% | - | 48,48% | - | 121,04% | 97,04% | 56,02% |
| Dividend per aandeel 2 | 48,00 | 48,00 | 48,00 | 100,0 | 120,0 | 120,0 | 120,0 | 122,5 |
| Datum van publicatie | 6/02/20 | 4/02/21 | 10/02/22 | 10/02/23 | 9/02/24 | - | - | - |
1JPY in Miljoen2JPY
Geschatte gegevens
Evolutie van de resultatenrekening (Kwartaalgegevens)
| Fiscaal tijdperk: december | 2020 S1 | 2021 S1 | 2021 Q3 | 2022 Q1 | 2022 S1 | 2022 Q3 | 2023 Q1 | 2023 S1 | 2023 Q3 | 2024 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|
| Omzet 1 | 19.857 | 21.555 | 11.882 | 10.960 | 23.102 | 12.213 | 11.811 | 25.699 | 13.433 | 13.451 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| Bedrijfsresultaat (EBIT) 1 | 2.738 | 1.788 | 1.365 | 1.292 | 2.682 | 1.384 | -437 | 1.510 | 1.701 | 1.383 |
| Operationele Marge | 13,79% | 8,3% | 11,49% | 11,79% | 11,61% | 11,33% | -3,7% | 5,88% | 12,66% | 10,28% |
| Resultaat voor belastingen (EBT) 1 | 2.128 | 1.786 | 1.405 | 1.246 | 2.655 | 1.450 | -405 | 1.540 | 1.772 | 1.160 |
| Nettowinst (verlies) 1 | 1.800 | 1.244 | 994 | 882 | 1.845 | 1.011 | -288 | 1.086 | 1.282 | 878 |
| Nettomarge | 9,06% | 5,77% | 8,37% | 8,05% | 7,99% | 8,28% | -2,44% | 4,23% | 9,54% | 6,53% |
| WPA 2 | 64,14 | 44,30 | 35,38 | 31,40 | 65,69 | 35,97 | -10,28 | 38,68 | 45,59 | 31,27 |
| Dividend per aandeel | 24,00 | 24,00 | - | - | 24,00 | - | - | 50,00 | - | - |
| Datum van publicatie | 31/07/20 | 30/07/21 | 29/10/21 | 28/04/22 | 29/07/22 | 31/10/22 | 28/04/23 | 31/07/23 | 31/10/23 | 26/04/24 |
1JPY in Miljoen2JPY
Geschatte gegevens
Balans
| Fiscaal tijdperk: december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Nettoschuldpositie | - | - | - | - | - | - | - | - |
| Nettokaspositie | 38.544 | 41.951 | 41.724 | 47.168 | 43.759 | - | - | - |
| Hefboom (schuld/ebitda) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 40.400 | 4.182 | -1.654 | 1.912 | -6.902 | 5.913 | 5.485 | 3.770 |
| ROE (netto-inkomsten/eigen vermogen) | 27,3% | 3,1% | 2,9% | 3,3% | 3,4% | 3,9% | 4,6% | 5,35% |
| ROA (netto-inkomsten/totale activa) | 1,39% | 3,74% | 3,77% | 4,19% | 3,97% | 3,5% | 4,15% | 4,75% |
| Totale activa 1 | 1.970.309 | 93.498 | 89.392 | 94.201 | 103.662 | 139.571 | 136.205 | 141.684 |
| Nettoactief per aandeel 2 | 4.029 | 4.098 | 4.165 | 4.243 | 4.274 | 4.312 | 4.402 | 4.520 |
| Cashflow per aandeel 2 | 1.010 | 145,0 | 135,0 | 157,0 | 163,0 | 182,0 | 188,0 | 208,0 |
| Capex 1 | 419 | 217 | 150 | 508 | 168 | 1.030 | 1.450 | 1.600 |
| Capex/omzet | 0,97% | 0,52% | 0,32% | 1,04% | 0,31% | 1,78% | 2,37% | 2,39% |
| Datum van publicatie | 6/02/20 | 4/02/21 | 10/02/22 | 10/02/23 | 9/02/24 | - | - | - |
1JPY in Miljoen2JPY
Geschatte gegevens
WPA & Dividend
Historische koers/winstverhouding
Evolutie van de historische prestaties
Historische marktkapitalisatie/EBITDA
Trading rating
Beleggingsrating
ESG Refinitiv
Herzieningen van WPA
| Vaira. 1 jan. | Kapi. | |
|---|---|---|
| +11,39% | 727 mln. | |
| +21,85% | 546 mld. | |
| -4,77% | 359 mld. | |
| +16,97% | 323 mld. | |
| +5,69% | 290 mld. | |
| +13,68% | 234 mld. | |
| +3,65% | 198 mld. | |
| -11,12% | 194 mld. | |
| +8,08% | 167 mld. | |
| -3,40% | 157 mld. |
- Beurs
- Aandelen
- Koers 4551
- Financiën Torii Pharmaceutical Co., Ltd.
